Qiagen N.V. $QGEN Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC cut its holdings in shares of Qiagen N.V. (NYSE:QGEN) by 43.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 182,834 shares of the company’s stock after selling 141,669 shares during the period. Voya Investment Management LLC owned about 0.08% of Qiagen worth $8,159,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in QGEN. SVB Wealth LLC bought a new stake in Qiagen in the first quarter valued at about $31,000. MAI Capital Management raised its stake in shares of Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after buying an additional 849 shares in the last quarter. Allworth Financial LP lifted its position in Qiagen by 260.1% in the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after purchasing an additional 796 shares during the period. Finally, Cullen Frost Bankers Inc. lifted its holdings in shares of Qiagen by 13,144.4% in the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after buying an additional 1,183 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on QGEN shares. Barclays reissued an “overweight” rating and set a $55.00 target price (up from $53.00) on shares of Qiagen in a research note on Monday, December 15th. Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and dropped their target price for the company from $55.00 to $50.00 in a report on Thursday, December 11th. Wall Street Zen upgraded Qiagen from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research report on Monday. Two research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $49.61.

Qiagen Price Performance

NYSE:QGEN opened at $45.62 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. The company has a fifty day moving average price of $46.26 and a 200 day moving average price of $47.13. Qiagen N.V. has a one year low of $37.63 and a one year high of $51.88. The stock has a market cap of $10.14 billion, a P/E ratio of 24.80, a PEG ratio of 2.35 and a beta of 0.68.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.03. The firm had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.57 earnings per share. Analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.